Endocannabinoid signalling in reward and addiction

Nature Reviews Neuroscience

Volumn 16, Issue 10, 2015, Pages 579-594

  Parsons, Loren H ^a   Hurd, Yasmin L ^b  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID RECEPTOR; ENDOCANNABINOID;

ADDICTION; AVOIDANCE BEHAVIOR; DNA POLYMORPHISM; DRUG ABUSE; DRUG DEPENDENCE; DRUG EXPOSURE; EMOTION; FOOD; HEREDITY; HUMAN; LEARNING; MEMORY; MOOD DISORDER; MOTIVATION; NERVE CELL PLASTICITY; NEUROBIOLOGY; NONHUMAN; PHYSIOLOGICAL PROCESS; PRIORITY JOURNAL; REVIEW; REWARD; SEXUAL BEHAVIOR; SIGNAL TRANSDUCTION; SOCIAL INTERACTION; STRESS; WITHDRAWAL SYNDROME; ANIMAL; BRAIN; CANNABIS ADDICTION; GENETICS; NERVE TRACT; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGY;

ANIMALS; BEHAVIOR, ADDICTIVE; BRAIN; ENDOCANNABINOIDS; HUMANS; MARIJUANA ABUSE; NEURAL PATHWAYS; REWARD; SIGNAL TRANSDUCTION;

EID: 84941877976     PISSN: 1471003X     EISSN: 14710048     Source Type: Journal    
DOI: 10.1038/nrn4004     Document Type: Review

References (214)

1. Glass, M., Dragunow, M., & Faull, R. L. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience. 77, 299-318 (1997
2. Wang, X., Dow-Edwards, D., Keller, E., & Hurd, Y. L. Preferential limbic expression of the cannabinoid receptor mRNA in the human fetal brain. Neuroscience. 118, 681-694 (2003
3. Atwood, B. K., & Mackie, K. CB2: a cannabinoid receptor with an identity crisis. Br. J Pharmacol. 160, 467-479 (2010
4. Salamone, J D., Correa, M., Mingote, S. M., & Weber, S. M. Beyond the reward hypothesis: alternative functions of nucleus accumbens dopamine. Curr. Opin. Pharmacol. 5, 34-41 (2005
5. Koob, G. F., & Volkow, N. D. Neurocircuitry of addiction. Neuropsychopharmacology. 35, 217-238 (2010
6. Everitt, B. J., et al. Neural mechanisms underlying the vulnerability to develop compulsive drug-seeking habits and addiction. Philos. Trans. R. Soc. B. 363, 3125-3135 (2008
7. Carlezon, W. A. Jr & Thomas, M. J Biological substrates of reward and aversion: a nucleus accumbens activity hypothesis. Neuropharmacology 56 (Suppl. 1), 122-132 (2009
8. Iemolo, A., et al. CRF-CRF1 receptor system in the central and basolateral nuclei of the amygdala differentially mediates excessive eating of palatable food. Neuropsychopharmacology. 38, 2456-2466 (2013
9. Herkenham, M., et al. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci. 11, 563-583 (1991
10. Sidhpura, N., & Parsons, L. H. Endocannabinoid-mediated synaptic plasticity and addiction-related behavior. Neuropharmacology. 61, 1070-1087 (2011
11. Panagis, G., Mackey, B., & Vlachou, S. Cannabinoid regulation of brain reward processing with an emphasis on the role of CB1 receptors: a step back into the future. Front. Psychiatry. 5, 92 (2014
12. Solinas, M., Justinova, Z., Goldberg, S. R., & Tanda, G. Anandamide administration alone and after inhibition of fatty acid amide hydrolase (FAAH) increases dopamine levels in the nucleus accumbens shell in rats. J Neurochem. 98, 408-419 (2006
13. Melis, M., & Pistis, M. Hub and switches: endocannabinoid signalling in midbrain dopamine neurons. Philos. Trans. R. Soc. B. 367, 3276-3285 (2012
14. Silvestri, C., & Di Marzo, V. The endocannabinoid system in energy homeostasis and the etiopathology of metabolic disorders. Cell. Metab. 17, 475-490 (2013
15. Klein, C., Hill, M. N., Chang, S. C., Hillard, C. J., & Gorzalka, B. B. Circulating endocannabinoid concentrations and sexual arousal in women. J Sex. Med. 9, 1588-1601 (2012
16. Trezza, V., Baarendse, P. J., & Vanderschuren, L. J The pleasures of play: pharmacological insights into social reward mechanisms. Trends Pharmacol. Sci. 31, 463-469 (2010
17. Fattore, L., et al. Cannabinoids and reward: interactions with the opioid system. Crit. Rev. Neurobiol. 16, 147-158 (2004
18. Di Marzo, V., et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature. 410, 822-825 (2001
19. Mechoulam, R., Hanus, L. O., Pertwee, R., & Howlett, A. C. Early phytocannabinoid chemistry to endocannabinoids and beyond. Nat. Rev. Neurosci. 15, 757-764 (2014
20. Vlachou, S., & Panagis, G. Regulation of brain reward by the endocannabinoid system: a critical review of behavioral studies in animals. Curr. Pharm. Des. 20, 2072-2088 (2014
21. Panlilio, L. V., Justinova, Z., & Goldberg, S. R. Inhibition of FAAH and activation of PPAR: new approaches to the treatment of cognitive dysfunction and drug addiction. Pharmacol. Ther. 138, 84-102 (2013
22. Wiley, J L., et al. Endocannabinoid contribution to ?9-Tetrahydrocannabinol discrimination in rodents. Eur. J Pharmacol. 737, 97-105 (2014
23. Long, J Z., et al. Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo. Proc. Natl Acad. Sci. USA. 106, 20270-20275 (2009
24. Justinova, Z., et al. Effects of fatty acid amide hydrolase (FAAH) inhibitors in non-human primate models of nicotine reward and relapse. Neuropsychopharmacology. 40, 2185-2197 (2015
25. Serrano, A., & Parsons, L. H. Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors. Pharmacol. Ther. 132, 215-241 (2011
26. Ellgren, M., Spano, S. M., & Hurd, Y. L. Adolescent cannabis exposure alters opiate intake and opioid limbic neuronal populations in adult rats. Neuropsychopharmacology. 32, 607-615 (2007
27. Cheer, J F., et al. Phasic dopamine release evoked by abused substances requires cannabinoid receptor activation. J Neurosci. 27, 791-795 (2007
28. Alvarez-Jaimes, L., & Parsons, L. H. Regional influence of CB1 receptor signaling on ethanol self-Administration by rats. Open Neuropsychopharmacol. J 2, 77-85 (2009
29. Simonnet, A., Cador, M., & Caille, S. Nicotine reinforcement is reduced by cannabinoid CB1 receptor blockade in the ventral tegmental area. Addict. Biol. 18, 930-936 (2013
30. Caille, S., Alvarez-Jaimes, L., Polis, I., Stouffer, D. G., & Parsons, L. H. Specific alterations of extracellular endocannabinoid levels in the nucleus accumbens by ethanol, heroin, and cocaine self-Administration. J Neurosci. 27, 3695-3702 (2007
31. D'Souza, M. S., & Markou, A. Neuronal mechanisms underlying development of nicotine dependence: implications for novel smoking-cessation treatments. Addict. Sci. Clin. Pract. 6, 4-16 (2011
32. Koob, G. F. Theoretical frameworks and mechanistic aspects of alcohol addiction: alcohol addiction as a reward deficit disorder. Curr. Top. Behav. Neurosci. 13, 3-30 (2013
33. Shippenberg, T. S., & Elmer, G. I. The neurobiology of opiate reinforcement. Crit. Rev. Neurobiol. 12, 267-303 (1998
34. Caille, S., & Parsons, L. H. Cannabinoid modulation of opiate reinforcement through the ventral striatopallidal pathway. Neuropsychopharmacology. 31, 804-813 (2006
35. Vlachou, S., Nomikos, G. G., & Panagis, G. WIN. 55, 212 2 decreases the reinforcing actions of cocaine through CB1 cannabinoid receptor stimulation. Behav. Brain Res. 141, 215-222 (2003
36. Fattore, L., Martellotta, M. C., Cossu, G., Mascia, M. S., & Fratta, W. CB1 cannabinoid receptor agonist WIN. 55, 212 2 decreases intravenous cocaine self-Administration in rats. Behav. Brain Res. 104, 141-146 (1999
37. Oliere, S., Joliette-Riopel, A., Potvin, S., & Jutras-Aswad, D. Modulation of the endocannabinoid system: vulnerability factor and new treatment target for stimulant addiction. Front. Psychiatry. 4, 109 (2013
38. Xi, Z. X., et al. Brain cannabinoid CB2 receptors modulate cocaine's actions in mice. Nat. Neurosci. 14, 1160-1166 (2011
39. Zhang, H. Y., et al. Species differences in cannabinoid receptor 2 and receptor responses to cocaine self-Administration in mice and rats. Neuropsychopharmacology. 40, 1037-1051 (2014
40. Ignatowska-Jankowska, B. M., Muldoon, P. P., Lichtman, A. H., & Damaj, M. I. The cannabinoid CB2 receptor is necessary for nicotine-conditioned place preference, but not other behavioral effects of nicotine in mice. Psychopharmacology. 229, 591-601 (2013
41. Navarrete, F., et al. Role of CB2 cannabinoid receptors in the rewarding, reinforcing, and physical effects of nicotine. Neuropsychopharmacology. 38, 2515-2524 (2013
42. Adamczyk, P., et al. The effects of cannabinoid CB1, CB2 and vanilloid TRPV1 receptor antagonists on cocaine addictive behavior in rats. Brain Res. 1444, 45-54 (2012
43. Gamaleddin, I., Zvonok, A., Makriyannis, A., Goldberg, S. R., & Le Foll, B. Effects of a selective cannabinoid CB2 agonist and antagonist on intravenous nicotine self administration and reinstatement of nicotine seeking. PLoS ONE. 7, e29900 (2012
44. Pava, M. J., & Woodward, J J A review of the interactions between alcohol and the endocannabinoid system: implications for alcohol dependence and future directions for research. Alcohol. 46, 185-204 (2012
45. Ceccarini, J., Casteels, C., Koole, M., Bormans, G., & Van Laere, K. Transient changes in the endocannabinoid system after acute and chronic ethanol exposure and abstinence in the rat: a combined PET and microdialysis study. Eur. J Nucl. Med. Mol. Imaging. 40, 1582-1594 (2013
46. Alvarez-Jaimes, L., Stouffer, D. G., & Parsons, L. H. Chronic ethanol treatment potentiates ethanol-induced increases in interstitial nucleus accumbens endocannabinoid levels in rats. J Neurochem. 111, 37-48 (2009
47. Malinen, H., & Hyytia, P. Ethanol self-Administration is regulated by CB1 receptors in the nucleus accumbens and ventral tegmental area in alcohol-preferring AA rats. Alcohol Clin. Exp. Res. 32, 1976-1983 (2008
48. Gonzalez, S., et al. Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine. Brain Res. 954, 73-81 (2002
49. Buczynski, M. W., Polis, I. Y., & Parsons, L. H. The volitional nature of nicotine exposure alters anandamide and oleoylethanolamide levels in the ventral tegmental area. Neuropsychopharmacology. 38, 574-584 (2013
50. Vigano, D., et al. Chronic morphine modulates the contents of the endocannabinoid, 2 arachidonoyl glycerol, in rat brain. Neuropsychopharmacology. 28, 1160-1167 (2003
51. Vigano, D., et al. Changes in endocannabinoid levels in a rat model of behavioural sensitization to morphine. Eur. J Neurosci. 20, 1849-1857 (2004
52. Patel, S., Rademacher, D. J., & Hillard, C. J Differential regulation of the endocannabinoids anandamide and 2 arachidonylglycerol within the limbic forebrain by dopamine receptor activity. J Pharmacol. Exp. Ther. 306, 880-888 (2003
53. Bystrowska, B., Smaga, I., Frankowska, M., & Filip, M. Changes in endocannabinoid and N acylethanolamine levels in rat brain structures following cocaine self-Administration and extinction training. Prog. Neuropsychopharmacol. Biol. Psychiatry. 50, 1-10 (2014
54. Rivera, P., et al. Cocaine self-Administration differentially modulates the expression of endogenous cannabinoid system-related proteins in the hippocampus of Lewis versus Fischer 344 rats. Int. J Neuropsychopharmacol. 16, 1277-1293 (2013
55. Palomino, A., et al. Effects of acute versus repeated cocaine exposure on the expression of endocannabinoid signaling-related proteins in the mouse cerebellum. Front. Integr. Neurosci. 8, 22 (2014
56. Gulyas, A. I., et al. Segregation of two endocannabinoid-hydrolyzing enzymes into pre- And postsynaptic compartments in the rat hippocampus, cerebellum and amygdala. Eur. J Neurosci. 20, 441-458 (2004
57. Kim, J., & Alger, B. E. Reduction in endocannabinoid tone is a homeostatic mechanism for specific inhibitory synapses. Nat. Neurosci. 13, 592-600 (2010
58. Merritt, L. L., Martin, B. R., Walters, C., Lichtman, A. H., & Damaj, M. I. The endogenous cannabinoid system modulates nicotine reward and dependence. J Pharmacol. Exp. Ther. 326, 483-492 (2008
59. Muldoon, P. P., Lichtman, A. H., Parsons, L. H., & Damaj, M. I. The role of fatty acid amide hydrolase inhibition in nicotine reward and dependence. Life Sci. 92, 458-462 (2013
60. Scherma, M., et al. Inhibition of anandamide hydrolysis by cyclohexyl carbamic acid 3? carbamoyl 3 yl ester (URB597) reverses abuse-related behavioral and neurochemical effects of nicotine in rats. J Pharmacol. Exp. Ther. 327, 482-490 (2008
61. Melis, M., & Pistis, M. Targeting the interaction between fatty acid ethanolamides and nicotinic receptors: therapeutic perspectives. Pharmacol. Res. 86, 42-49 (2014
62. Blednov, Y. A., Cravatt, B. F., Boehm, S. L. 2nd, Walker, D., & Harris, R. A. Role of endocannabinoids in alcohol consumption and intoxication: studies of mice lacking fatty acid amide hydrolase. Neuropsychopharmacology. 32, 1570-1582 (2007
63. Vinod, K. Y., Sanguino, E., Yalamanchili, R., Manzanares, J., & Hungund, B. L. Manipulation of fatty acid amide hydrolase functional activity alters sensitivity and dependence to ethanol. J Neurochem. 104, 233-243 (2008
64. Hansson, A. C., et al. Genetic impairment of frontocortical endocannabinoid degradation and high alcohol preference. Neuropsychopharmacology. 32, 117-126 (2007
65. Cippitelli, A., et al. Increase of brain endocannabinoid anandamide levels by FAAH inhibition and alcohol abuse behaviours in the rat. Psychopharmacology. 198, 449-460 (2008
66. Justinova, Z., et al. Fatty acid amide hydrolase inhibition heightens anandamide signaling without producing reinforcing effects in primates. Biol. Psychiatry. 64, 930-937 (2008
67. Luchicchi, A., et al. Effects of fatty acid amide hydrolase inhibition on neuronal responses to nicotine, cocaine and morphine in the nucleus accumbens shell and ventral tegmental area: involvement of PPAR-a nuclear receptors. Addict. Biol. 15, 277-288 (2010
68. Lovinger, D. M. Presynaptic modulation by endocannabinoids. Handb. Exp. Pharmacol. 184, 435-477 (2008
69. Mereu, M., et al. Cocaine-induced endocannabinoid release modulates behavioral and neurochemical sensitization in mice. Addict. Biol. 20, 91-103 (2013
70. Scherma, M., et al. The anandamide transport inhibitor AM404 reduces the rewarding effects of nicotine and nicotine-induced dopamine elevations in the nucleus accumbens shell in rats. Br. J Pharmacol. 165, 2539-2548 (2012
71. Gamaleddin, I., Guranda, M., Goldberg, S. R., & Le Foll, B. The selective anandamide transport inhibitor VDM11 attenuates reinstatement of nicotine seeking behaviour, but does not affect nicotine intake. Br. J Pharmacol. 164, 1652-1660 (2011
72. Gamaleddin, I., et al. AM404 attenuates reinstatement of nicotine seeking induced by nicotine-Associated cues and nicotine priming but does not affect nicotine-And food-Taking. J Psychopharmacol. 27, 564-571 (2013
73. Vlachou, S., Stamatopoulou, F., Nomikos, G. G., & Panagis, G. Enhancement of endocannabinoid neurotransmission through CB1 cannabinoid receptors counteracts the reinforcing and psychostimulant effects of cocaine. Int. J Neuropsychopharmacol. 11, 905-923 (2008
74. Ducci, F., & Goldman, D. The genetic basis of addictive disorders. Psychiatr. Clin. North Am. 35, 495-519 (2012
75. Nestler, E. J Epigenetic mechanisms of drug addiction. Neuropharmacology. 76, 259-268 (2014
76. Hirvonen, J., et al. Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers. Mol. Psychiatry. 17, 642-649 (2012
77. Ceccarini, J., et al. [18F]MK 9470 PET measurement of cannabinoid CB1 receptor availability in chronic cannabis users. Addict. Biol. 20, 357-367 (2015
78. Breivogel, C. S., et al. Chronic ?9-Tetrahydrocannabinol treatment produces a time-dependent loss of cannabinoid receptors and cannabinoid receptor-Activated G proteins in rat brain. J Neurochem. 73, 2447-2459 (1999
79. Sim, L. J., Hampson, R. E., Deadwyler, S. A., & Childers, S. R. Effects of chronic treatment with ?9-Tetrahydrocannabinol on cannabinoid-stimulated [35S]GTP?S autoradiography in rat brain. J Neurosci. 16, 8057-8066 (1996
80. Dudok, B., et al. Cell-specific STORM super-resolution imaging reveals nanoscale organization of cannabinoid signaling. Nat. Neurosci. 18, 75-86 (2015
81. Puighermanal, E., Busquets-Garcia, A., Maldonado, R., & Ozaita, A. Cellular and intracellular mechanisms involved in the cognitive impairment of cannabinoids. Phil. Trans. R. Soc. B. 367, 3254-3263 (2012
82. Di Marzo, V., et al. Enhancement of anandamide formation in the limbic forebrain and reduction of endocannabinoid contents in the striatum of ?9-Tetrahydrocannabinol-Tolerant rats. J Neurochem. 74, 1627-1635 (2000
83. Schlosburg, J E., et al. Inhibitors of endocannabinoid-metabolizing enzymes reduce precipitated withdrawal responses in THC-dependent mice. AAPS J 11, 342-352 (2009
84. Leweke, F. M., et al. Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use. Schizophr. Res. 94, 29-36 (2007
85. Morgan, C. J., et al. Cerebrospinal fluid anandamide levels, cannabis use and psychotic-like symptoms. Br. J Psychiatry. 202, 381-382 (2013
86. Muhl, D., et al. Increased CB2 mRNA and anandamide in human blood after cessation of cannabis abuse. Naunyn Schmiedebergs Arch. Pharmacol. 387, 691-695 (2014
87. Lutz, B. Endocannabinoid signals in the control of emotion. Curr. Opin. Pharmacol. 9, 46-52 (2009
88. Murillo-Rodriguez, E., et al. The emerging role of the endocannabinoid system in the sleep-wake cycle modulation. Cent. Nerv. Syst. Agents Med. Chem. 11, 189-196 (2011
89. Budney, A. J., Hughes, J R., Moore, B. A., & Novy, P. L. Marijuana abstinence effects in marijuana smokers maintained in their home environment. Arch. Gen. Psychiatry. 58, 917-924 (2001
90. Gates, P., Albertella, L., & Copeland, J Cannabis withdrawal and sleep: a systematic review of human studies. Subst. Abus. http://dx.doi.org/10.1080/0889 7077.2015.1023484 (2015
91. Serrano, A., et al. Differential effects of single versus repeated alcohol withdrawal on the expression of endocannabinoid system-related genes in the rat amygdala. Alcohol Clin. Exp. Res. 36, 984-994 (2012
92. Mitrirattanakul, S., et al. Bidirectional alterations of hippocampal cannabinoid 1 receptors and their endogenous ligands in a rat model of alcohol withdrawal and dependence. Alcohol Clin. Exp. Res. 31, 855-867 (2007
93. Vinod, K. Y., et al. Selective alterations of the CB1 receptors and the fatty acid amide hydrolase in the ventral striatum of alcoholics and suicides. J Psychiatr. Res. 44, 591-597 (2010
94. Hirvonen, J., et al. Reduced cannabinoid CB1 receptor binding in alcohol dependence measured with positron emission tomography. Mol. Psychiatry. 18, 916-921 (2013
95. Ceccarini, J., et al. Changes in cerebral CB1 receptor availability after acute and chronic alcohol abuse and monitored abstinence. J Neurosci. 34, 2822-2831 (2014
96. Neumeister, A., et al. Positron emission tomography shows elevated cannabinoid CB1 receptor binding in men with alcohol dependence. Alcohol Clin. Exp. Res. 36, 2104-2109 (2012
97. Vinod, K. Y., Yalamanchili, R., Xie, S., Cooper, T. B., & Hungund, B. L. Effect of chronic ethanol exposure and its withdrawal on the endocannabinoid system. Neurochem. Int. 49, 619-625 (2006
98. Werling, L. L., Reed, S. C., Wade, D., & Izenwasser, S. Chronic nicotine alters cannabinoid-mediated locomotor activity and receptor density in periadolescent but not adult male rats. Int. J Dev. Neurosci. 27, 263-269 (2009
99. Marco, E. M., et al. Subchronic nicotine exposure in adolescence induces long-Term effects on hippocampal and striatal cannabinoid CB1 and mu opioid receptors in rats. Eur. J Pharmacol. 557, 37-43 (2007
100. Rubino, T., Tizzoni, L., Vigano, D., Massi, P., & Parolaro, D. Modulation of rat brain cannabinoid receptors after chronic morphine treatment. Neuroreport. 8, 3219-3223 (1997
101. Cichewicz, D. L., Haller, V. L., & Welch, S. P. Changes in opioid and cannabinoid receptor protein following short-Term combination treatment with ?9-Tetrahydrocannabinol and morphine. J Pharmacol. Exp. Ther. 297, 121-127 (2001
102. Adamczyk, P., et al. Long-lasting increase in [3H] CP55, 940 binding to CB1 receptors following cocaine self-Administration and its withdrawal in rats. Brain Res. 1451, 34-43 (2012
103. Pavon, F. J., et al. Evaluation of plasma-free endocannabinoids and their congeners in abstinent cocaine addicts seeking outpatient treatment: impact of psychiatric co morbidity. Addict. Biol. 18, 955-969 (2013
104. Heifets, B. D., & Castillo, P. E. Endocannabinoid signaling and long-Term synaptic plasticity. Annu. Rev. Physiol. 71, 283-306 (2009
105. Adermark, L., Jonsson, S., Ericson, M., & Soderpalm, B. Intermittent ethanol consumption depresses endocannabinoid-signaling in the dorsolateral striatum of rat. Neuropharmacology. 61, 1160-1165 (2011
106. Clarke, R. B., & Adermark, L. Acute ethanol treatment prevents endocannabinoid-mediated long-lasting disinhibition of striatal output. Neuropharmacology. 58, 799-805 (2010
107. DePoy, L., et al. Chronic alcohol produces neuroadaptations to prime dorsal striatal learning. Proc. Natl Acad. Sci. USA. 110, 14783-14788 (2013
108. Fourgeaud, L., et al. A single in vivo exposure to cocaine abolishes endocannabinoid-mediated long-Term depression in the nucleus accumbens. J Neurosci. 24, 6939-6945 (2004
109. Pan, B., Hillard, C. J., & Liu, Q. S. Endocannabinoid signaling mediates cocaine-induced inhibitory synaptic plasticity in midbrain dopamine neurons. J Neurosci. 28, 1385-1397 (2008
110. Liu, Q. S., Pu, L., & Poo, M. M. Repeated cocaine exposure in vivo facilitates LTP induction in midbrain dopamine neurons. Nature. 437, 1027-1031 (2005
111. Grueter, B. A., et al. Extracellular-signal regulated kinase 1 dependent metabotropic glutamate receptor 5 induced long-Term depression in the bed nucleus of the stria terminalis is disrupted by cocaine administration. J Neurosci. 26, 3210-3219 (2006
112. McElligott, Z. A., & Winder, D. G. Modulation of glutamatergic synaptic transmission in the bed nucleus of the stria terminalis. Prog. Neuropsychopharmacol. Biol. Psychiatry. 33, 1329-1335 (2009
113. Hoffman, A. F., Oz, M., Caulder, T., & Lupica, C. R. Functional tolerance and blockade of long-Term depression at synapses in the nucleus accumbens after chronic cannabinoid exposure. J Neurosci. 23, 4815-4820 (2003
114. Mato, S., et al. A single in vivo exposure to ?9THC blocks endocannabinoid-mediated synaptic plasticity. Nat. Neurosci. 7, 585-586 (2004
115. Reisiger, A. R., et al. Nicotine self-Administration induces CB1 dependent LTP in the bed nucleus of the stria terminalis. J Neurosci. 34, 4285-4292 (2014
116. Koob, G., & Kreek, M. J Stress, dysregulation of drug reward pathways, and the transition to drug dependence. Am. J Psychiatry. 164, 1149-1159 (2007
117. Morena, M., Patel, S., Bains, J S., & Hill, M. N. Neurobiological interactions between stress and the endocannabinoid system. Neuropsychopharmacology http://dx.doi.org/10.1038/npp.2015.166 (2015
118. Ruehle, S., Rey, A. A., Remmers, F., & Lutz, B. The endocannabinoid system in anxiety, fear memory and habituation. J Psychopharmacol. 26, 23-39 (2012
119. Bura, S. A., Burokas, A., Martin-Garcia, E., & Maldonado, R. Effects of chronic nicotine on food intake and anxiety-like behaviour in CB1 knockout mice. Eur. Neuropsychopharmacol. 20, 369-378 (2010
120. Cippitelli, A., et al. Endocannabinoid regulation of acute and protracted nicotine withdrawal: effect of FAAH inhibition. PLoS ONE. 6, e28142 (2011
121. Mannucci, C., et al. Interactions between endocannabinoid and serotonergic systems in mood disorders caused by nicotine withdrawal. Nicotine Tob. Res. 13, 239-247 (2011
122. McKinzie, D. L., et al. Acoustic startle and fear-potentiated startle in alcohol-preferring (P) and -nonpreferring (NP) lines of rats. Pharmacol. Biochem. Behav. 65, 691-696 (2000
123. Barrenha, G. D., & Chester, J A. Genetic correlation between innate alcohol preference and fear-potentiated startle in selected mouse lines. Alcohol Clin. Exp. Res. 31, 1081-1088 (2007
124. Powers, M. S., Barrenha, G. D., Mlinac, N. S., Barker, E. L., & Chester, J A. Effects of the novel endocannabinoid uptake inhibitor, LY2183240, on fear-potentiated startle and alcohol-seeking behaviors in mice selectively bred for high alcohol preference. Psychopharmacology. 212, 571-583 (2010
125. Gunduz-Cinar, O., Hill, M. N., McEwen, B. S., & Holmes, A. Amygdala FAAH and anandamide: mediating protection and recovery from stress. Trends Pharmacol. Sci. 34, 637-644 (2013
126. Marsicano, G., & Lafenetre, P. Roles of the endocannabinoid system in learning and memory. Curr. Top. Behav. Neurosci. 1, 201-230 (2009
127. Carter, B. L., & Tiffany, S. T. Cue-reactivity and the future of addiction research. Addiction. 94, 349-351 (1999
128. De Vries, T. J., & Schoffelmeer, A. N. Cannabinoid CB1 receptors control conditioned drug seeking. Trends Pharmacol. Sci. 26, 420-426 (2005
129. Fattore, L., et al. An endocannabinoid mechanism in relapse to drug seeking: a review of animal studies and clinical perspectives. Brain Res. Rev. 53, 1-16 (2007
130. Alvarez-Jaimes, L., Polis, I., & Parsons, L. H. Attenuation of cue-induced heroin-seeking behavior by cannabinoid CB1 antagonist infusions into the nucleus accumbens core and prefrontal cortex, but not basolateral amygdala. Neuropsychopharmacology. 33, 2483-2493 (2008
131. Kodas, E., Cohen, C., Louis, C., & Griebel, G. Cortico-limbic circuitry for conditioned nicotine-seeking behavior in rats involves endocannabinoid signaling. Psychopharmacology. 194, 161-171 (2007
132. De Vries, T. J., de Vries, W., Janssen, M. C., & Schoffelmeer, A. N. Suppression of conditioned nicotine and sucrose seeking by the cannabinoid 1 receptor antagonist SR141716A. Behav. Brain Res. 161, 164-168 (2005
133. Ward, S. J., Rosenberg, M., Dykstra, L. A., & Walker, E. A. The CB1 antagonist rimonabant (SR141716) blocks cue-induced reinstatement of cocaine seeking and other context and extinction phenomena predictive of relapse. Drug Alcohol Depend. 105, 248-255 (2009
134. Xi, Z. X., et al. Cannabinoid CB1 receptor antagonist AM251 inhibits cocaine-primed relapse in rats: role of glutamate in the nucleus accumbens. J Neurosci. 26, 8531-8536 (2006
135. De Petrocellis, L., Bisogno, T., Davis, J B., Pertwee, R. G., & Di Marzo, V. Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-like activity. FEBS Lett. 483, 52-56 (2000
136. van der Stelt, M., et al. Endocannabinoids and β-Amyloid-induced neurotoxicity in vivo: effect of pharmacological elevation of endocannabinoid levels. Cell. Mol. Life Sci. 63, 1410-1424 (2006
137. Cippitelli, A., et al. The anandamide transport inhibitor AM404 reduces ethanol self-Administration. Eur. J Neurosci. 26, 476-486 (2007
138. Mangieri, R. A., Hong, K. I., Piomelli, D., & Sinha, R. An endocannabinoid signal associated with desire for alcohol is suppressed in recently abstinent alcoholics. Psychopharmacology. 205, 63-72 (2009
139. Conklin, C. A., & Tiffany, S. T. Applying extinction research and theory to cue-exposure addiction treatments. Addiction. 97, 155-167 (2002
140. Crombag, H. S., & Shaham, Y. Renewal of drug seeking by contextual cues after prolonged extinction in rats. Behav. Neurosci. 116, 169-173 (2002
141. Marsicano, G., et al. The endogenous cannabinoid system controls extinction of aversive memories. Nature. 418, 530-534 (2002
142. Lutz, B. The endocannabinoid system and extinction learning. Mol. Neurobiol. 36, 92-101 (2007
143. Kaplan, G. B., Heinrichs, S. C., & Carey, R. J Treatment of addiction and anxiety using extinction approaches: neural mechanisms and their treatment implications. Pharmacol. Biochem. Behav. 97, 619-625 (2011
144. Kendler, K. S., Karkowski, L. M., Neale, M. C., & Prescott, C. A. Illicit psychoactive substance use, heavy use, abuse, and dependence in a US population-based sample of male twins. Arch. Gen. Psychiatry. 57, 261-269 (2000
145. Agrawal, A., & Lynskey, M. T. Are there genetic influences on addiction: evidence from family, adoption and twin studies. Addiction. 103, 1069-1081 (2008
146. Hillard, C. J., Weinlander, K. M., & Stuhr, K. L. Contributions of endocannabinoid signaling to psychiatric disorders in humans: genetic and biochemical evidence. Neuroscience. 204, 207-229 (2012
147. Lopez-Moreno, J A., Echeverry-Alzate, V., & Buhler, K. M. The genetic basis of the endocannabinoid system and drug addiction in humans. J Psychopharmacol. 26, 133-143 (2012
148. Zhang, P. W., et al. Human cannabinoid receptor 1: 5? exons, candidate regulatory regions, polymorphisms, haplotypes and association with polysubstance abuse. Mol. Psychiatry. 9, 916-931 (2004
149. Schroth, G. P., Chou, P. J., & Ho, P. S. Mapping Z DNA in the human genome. Computer-Aided mapping reveals a nonrandom distribution of potential Z DNA-forming sequences in human genes. J Biol. Chem. 267, 11846-11855 (1992
150. Comings, D. E., et al. Cannabinoid receptor gene (CNR1): association with i.v. drug use. Mol. Psychiatry. 2, 161-168 (1997
151. Ballon, N., et al. (AAT)n repeat in the cannabinoid receptor gene (CNR1): association with cocaine addiction in an African-Caribbean population. Pharmacogenomics J 6, 126-130 (2006
152. Covault, J., Gelernter, J., & Kranzler, H. Association study of cannabinoid receptor gene (CNR1) alleles and drug dependence. Mol. Psychiatry. 6, 501-502 (2001
153. Benyamina, A., Kebir, O., Blecha, L., Reynaud, M., & Krebs, M. O. CNR1 gene polymorphisms in addictive disorders: a systematic review and a meta-Analysis. Addict. Biol. 16, 1-6 (2011
154. Schmidt, L. G., et al. Association of a CB1 cannabinoid receptor gene (CNR1) polymorphism with severe alcohol dependence. Drug Alcohol Depend. 65, 221-224 (2002
155. Ehlers, C. L., Slutske, W. S., Lind, P. A., & Wilhelmsen, K. C. Association between single nucleotide polymorphisms in the cannabinoid receptor gene (CNR1) and impulsivity in southwest California Indians. Twin Res. Hum. Genet. 10, 805-811 (2007
156. Proudnikov, D., et al. Association of Polymorphisms of the Cannabinoid Receptor (CNR1) and Fatty Acid Amide Hydrolase (FAAH) Genes with Heroin Addiction: Impact of Long Repeats of CNR1. Pharmacogenomics J 10, 232-242 (2010
157. Li, M. J., et al. GWASdb: a database for human genetic variants identified by genome-wide association studies. Nucleic Acids Res. 40, D1047-D1054 (2012
158. van den Wildenberg, E., Janssen, R. G., Hutchison, K. E., van Breukelen, G. J., & Wiers, R. W. Polymorphisms of the dopamine D4 receptor gene (DRD4 VNTR) and cannabinoid CB1 receptor gene (CNR1) are not strongly related to cue-reactivity after alcohol exposure. Addict. Biol. 12, 210-220 (2007
159. Haughey, H. M., Marshall, E., Schacht, J P., Louis, A., & Hutchison, K. E. Marijuana withdrawal and craving: influence of the cannabinoid receptor 1 (CNR1) and fatty acid amide hydrolase (FAAH) genes. Addiction. 103, 1678-1686 (2008
160. Filbey, F. M., Schacht, J P., Myers, U. S., Chavez, R. S., & Hutchison, K. E. Individual and additive effects of the CNR1 and FAAH genes on brain response to marijuana cues. Neuropsychopharmacology. 35, 967-975 (2010
161. Hutchison, K. E., et al. The incentive salience of alcohol: translating the effects of genetic variant in CNR1. Arch. Gen. Psychiatry. 65, 841-850 (2008
162. Agrawal, A., et al. Evidence for association between polymorphisms in the cannabinoid receptor 1 (CNR1) gene and cannabis dependence. Am. J Med. Genet. B Neuropsychiatr. Genet. 150B, 736-740 (2009
163. Hopfer, C. J., et al. Cannabis receptor haplotype associated with fewer cannabis dependence symptoms in adolescents. Am. J Med. Genet. B Neuropsychiatr. Genet. 141B, 895-901 (2006
164. Hartman, C. A., et al. The association between cannabinoid receptor 1 gene (CNR1) and cannabis dependence symptoms in adolescents and young adults. Drug Alcohol Depend. 104, 11-16 (2009
165. Herman, A. I., Kranzler, H. R., Cubells, J F., Gelernter, J., & Covault, J Association study of the CNR1 gene exon 3 alternative promoter region polymorphisms and substance dependence. Am. J Med. Genet. B Neuropsychiatr. Genet. 141B, 499-503 (2006
166. Sipe, J C., Chiang, K., Gerber, A. L., Beutler, E., & Cravatt, B. F. A missense mutation in human fatty acid amide hydrolase associated with problem drug use. Proc. Natl Acad. Sci. USA. 99, 8394-8399 (2002
167. Chiang, K. P., Gerber, A. L., Sipe, J C., & Cravatt, B. F. Reduced cellular expression and activity of the P129T mutant of human fatty acid amide hydrolase: evidence for a link between defects in the endocannabinoid system and problem drug use. Hum. Mol. Genet. 13, 2113-2119 (2004
168. Tyndale, R. F., Payne, J I., Gerber, A. L., & Sipe, J C. The fatty acid amide hydrolase C385A (P129T) missense variant in cannabis users: studies of drug use and dependence in Caucasians. Am. J Med. Genet. B Neuropsychiatr. Genet. 144B, 660-666 (2007
169. Buhler, K. M., et al. Risky alcohol consumption in young people is associated with the fatty acid amide hydrolase gene polymorphism C385A and affective rating of drug pictures. Mol. Genet. Genomics. 289, 279-289 (2014
170. Hariri, A. R., et al. Divergent effects of genetic variation in endocannabinoid signaling on human threat- And reward-related brain function. Biol. Psychiatry. 66, 9-16 (2009
171. Glahn, D. C., Lovallo, W. R., & Fox, P. T. Reduced amygdala activation in young adults at high risk of alcoholism: studies from the Oklahoma family health patterns project. Biol. Psychiatry. 61, 1306-1309 (2007
172. Maccarrone, M., Guzman, M., Mackie, K., Doherty, P., & Harkany, T. Programming of neural cells by (endo) cannabinoids: from physiological rules to emerging therapies. Nat. Rev. Neurosci. 15, 786-801 (2014
173. Hurd, Y. L., Michaelides, M., Miller, M. L., & Jutras-Aswad, D. Trajectory of adolescent cannabis use on addiction vulnerability. Neuropharmacology. 76, 416-424 (2014
174. Calvigioni, D., Hurd, Y. L., Harkany, T., & Keimpema, E. Neuronal substrates and functional consequences of prenatal cannabis exposure. Eur. Child Adolesc. Psychiatry. 23, 931-941 (2014
175. Gorzalka, B. B., & Dang, S. S. Minireview: endocannabinoids and gonadal hormones: bidirectional interactions in physiology and behavior. Endocrinology. 153, 1016-1024 (2012
176. Stoving, R. K., et al. Leptin, ghrelin, and endocannabinoids: potential therapeutic targets in anorexia nervosa. J Psychiatr. Res. 43, 671-679 (2009
177. Monteleone, P., et al. Hedonic eating is associated with increased peripheral levels of ghrelin and the endocannabinoid 2 arachidonoyl-glycerol in healthy humans: a pilot study. J Clin. Endocrinol. Metab. 97, E917-E924 (2012
178. Monteleone, P., et al. Blood levels of the endocannabinoid anandamide are increased in anorexia nervosa and in binge-eating disorder, but not in bulimia nervosa. Neuropsychopharmacology. 30, 1216-1221 (2005
179. Siegfried, Z., et al. Association study of cannabinoid receptor gene (CNR1) alleles and anorexia nervosa: differences between restricting and binging/purging subtypes. Am. J Med. Genet. B Neuropsychiatr. Genet. 125B, 126-130 (2004
180. Muller, T. D., et al. Lack of association of genetic variants in genes of the endocannabinoid system with anorexia nervosa. Child Adolesc. Psychiatry Ment. Health. 2, 33 (2008
181. Monteleone, P., et al. Association of CNR1 and FAAH endocannabinoid gene polymorphisms with anorexia nervosa and bulimia nervosa: evidence for synergistic effects. Genes Brain Behav. 8, 728-732 (2009
182. Sipe, J C., Waalen, J., Gerber, A., & Beutler, E. Overweight and obesity associated with a missense polymorphism in fatty acid amide hydrolase (FAAH). Int. J Obes. 29, 755-759 (2005
183. Frieling, H., et al. Elevated cannabinoid 1 receptor mRNA is linked to eating disorder related behavior and attitudes in females with eating disorders. Psychoneuroendocrinology. 34, 620-624 (2009
184. Gerard, N., Pieters, G., Goffin, K., Bormans, G., & Van Laere, K. Brain type 1 cannabinoid receptor availability in patients with anorexia and bulimia nervosa. Biol. Psychiatry. 70, 777-784 (2011
185. Ishiguro, H., et al. A nonsynonymous polymorphism in cannabinoid CB2 receptor gene is associated with eating disorders in humans and food intake is modified in mice by its ligands. Synapse. 64, 92-96 (2010
186. Verty, A. N., McGregor, I. S., & Mallet, P. E. Paraventricular hypothalamic CB1 cannabinoid receptors are involved in the feeding stimulatory effects of ?9-Tetrahydrocannabinol. Neuropharmacology. 49, 1101-1109 (2005
187. Lewis, D. Y., & Brett, R. R. Activity-based anorexia in C57/BL6 mice: effects of the phytocannabinoid, ?9-Tetrahydrocannabinol (THC) and the anandamide analogue, OMDM 2. Eur. Neuropsychopharmacol. 20, 622-631 (2010
188. Andries, A., Frystyk, J., Flyvbjerg, A., & Stoving, R. K. Dronabinol in severe, enduring anorexia nervosa: a randomized controlled trial. Int. J Eat. Disord. 47, 18-23 (2014
189. Pataky, Z., et al. Efficacy of rimonabant in obese patients with binge eating disorder. Exp. Clin. Endocrinol. Diabetes. 121, 20-26 (2013
190. Scherma, M., et al. Pharmacological modulation of the endocannabinoid signalling alters binge-Type eating behaviour in female rats. Br. J Pharmacol. 169, 820-833 (2013
191. Cottone, P., et al. CRF system recruitment mediates dark side of compulsive eating. Proc. Natl Acad. Sci. USA. 106, 20016-20020 (2009
192. Koob, G. F. The role of CRF and CRF-related peptides in the dark side of addiction. Brain Res. 1314, 3-14 (2010
193. Blasio, A., et al. Rimonabant precipitates anxiety in rats withdrawn from palatable food: role of the central amygdala. Neuropsychopharmacology. 38, 2498-2507 (2013
194. D'Addario, C., Di Francesco, A., Pucci, M., Finazzi Agro, A., & Maccarrone, M. Epigenetic mechanisms and endocannabinoid signalling. FEBS J 280, 1905-1917 (2013
195. Franklin, T. B., et al. Epigenetic transmission of the impact of early stress across generations. Biol. Psychiatry. 68, 408-415 (2010
196. Rotter, A., et al. CB1 and CB2 receptor expression and promoter methylation in patients with cannabis dependence. Eur. Addict. Res. 19, 13-20 (2013
197. DiNieri, J A., et al. Maternal cannabis use alters ventral striatal dopamine D2 gene regulation in the offspring. Biol. Psychiatry. 70, 763-769 (2011
198. Tomasiewicz, H. C., et al. Proenkephalin mediates the enduring effects of adolescent cannabis exposure associated with adult opiate vulnerability. Biol. Psychiatry. 72, 803-810 (2012
199. Stringer, R. L., Laufer, B. I., Kleiber, M. L., & Singh, S. M. Reduced expression of brain cannabinoid receptor 1 (Cnr1) is coupled with an increased complementary micro-RNA (miR 26b) in a mouse model of fetal alcohol spectrum disorders. Clin. Epigenetics. 5, 14 (2013
200. Matyas, F., et al. Identification of the sites of 2 arachidonoylglycerol synthesis and action imply retrograde endocannabinoid signaling at both GABAergic and glutamatergic synapses in the ventral tegmental area. Neuropharmacology. 54, 95-107 (2008
201. Suárez, J., et al. Distribution of diacylglycerol lipase alpha, an endocannabinoid synthesizing enzyme, in the rat forebrain. Neuroscience. 192, 112-131 (2011
202. Egertova, M., Simon, G. M., Cravatt, B. F., & Elphick, M. R. Localization of N acyl phosphatidylethanolamine phospholipase D (NAPE-PLD) expression in mouse brain: a new perspective on N acylethanolamines as neural signaling molecules. J Comp. Neurol. 506, 604-615 (2008
203. Egertova, M., & Elphick, M. R. Localisation of cannabinoid receptors in the rat brain using antibodies to the intracellular C terminal tail of CB. J Comp. Neurol. 422, 159-171 (2000
204. Matyas, F., et al. Subcellular localization of type 1 cannabinoid receptors in the rat basal ganglia. Neuroscience. 137, 337-361 (2006
205. Lecca, S., Melis, M., Luchicchi, A., Muntoni, A. L., & Pistis, M. Inhibitory inputs from rostromedial tegmental neurons regulate spontaneous activity of midbrain dopamine cells and their responses to drugs of abuse. Neuropsychopharmacology. 37, 1164-1176 (2012
206. Riegel, A. C., & Lupica, C. R. Independent presynaptic and postsynaptic mechanisms regulate endocannabinoid signaling at multiple synapses in the ventral tegmental area. J Neurosci. 24, 11070-11078 (2004
207. Kortleven, C., Fasano, C., Thibault, D., Lacaille, J C., & Trudeau, L. E. The endocannabinoid 2 arachidonoylglycerol inhibits long-Term potentiation of glutamatergic synapses onto ventral tegmental area dopamine neurons in mice. Eur. J Neurosci. 33, 1751-1760 (2011
208. Marinelli, S., et al. N arachidonoyl-dopamine tunes synaptic transmission onto dopaminergic neurons by activating both cannabinoid and vanilloid receptors. Neuropsychopharmacology. 32, 298-308 (2007
209. Kravitz, A. V., Tye, L. D., & Kreitzer, A. C. Distinct roles for direct and indirect pathway striatal neurons in reinforcement. Nat. Neurosci. 15, 816-818 (2012
210. Stuber, G. D., et al. Reward-predictive cues enhance excitatory synaptic strength onto midbrain dopamine neurons. Science. 321, 1690-1692 (2008
211. Robbe, D., Alonso, G., Duchamp, F., Bockaert, J., & Manzoni, O. J Localization and mechanisms of action of cannabinoid receptors at the glutamatergic synapses of the mouse nucleus accumbens. J Neurosci. 21, 109-116 (2001
212. Grueter, B. A., Brasnjo, G., & Malenka, R. C. Postsynaptic TRPV1 triggers cell type-specific long-Term depression in the nucleus accumbens. Nat. Neurosci. 13, 1519-1525 (2010
213. Giuffrida, A., et al. Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat. Neurosci. 2, 358-363 (1999
214. Winters, B. D., et al. Cannabinoid receptor 1 expressing neurons in the nucleus accumbens. Proc. Natl Acad. Sci. USA. 109, E2717-E2725 (2012